Integral BioStrategy Research
Integral BioStrategy Research is the firm's publication of evidence-graded analysis on metabolic-disease strategy — longer Strategy Reports and shorter Insight essays — written for the teams developing, funding, evaluating, and paying for these therapies.
What it is
It is a research and analysis publication — not a peer-reviewed journal. Each piece is original strategic analysis that synthesizes published evidence, regulatory and market dynamics, and development logic into a decision-useful argument. The work is self-published by Integral BioStrategy and intended to be read, cited, and built on.
Editorial standards
Every report and essay is reviewed and graded before publication. In practice:
- Sourced. Load-bearing claims are anchored to primary or regulatory sources, each shown with a source-quality grade; estimates are labeled as estimates, not facts.
- Disciplined. Trial findings are kept distinct from approvals and labels; causal language is calibrated to the evidence; each piece states explicitly what it does not claim.
- Scored. Each piece is assessed against a written quality rubric — clarity, logic, evidence, and decision relevance — before it is published.
- Restrained. This is scientific and strategic analysis, not advice (see the notice below).
Authorship & contributions
Integral BioStrategy Research is authored by Ivan A. Valdez, PhD, with input from the firm's advisory network engaged by scope. Invited contributions from outside experts are welcome and are held to the same editorial and evidence standards — editorial review, not peer review.
How to cite
Each piece carries a suggested citation and, where registered, a persistent identifier (DOI). Machine-readable citation metadata is embedded in every page for reference managers (Zotero, Mendeley) and Google Scholar.
Author. Title. Integral BioStrategy Research; Year. URL. doi: (where available).
Pieces are © Integral BioStrategy and published under CC BY 4.0 — reuse and quote with attribution.
The series
- Strategy Reports — evidence-graded, decision-grade analyses.
- Insights — shorter essays that frame a problem or pattern.
Published to date — each with a registered DOI, citable in proposals, decks, and the literature.
- Metabolism as Platform Medicine — Strategy Report, June 2026. doi: 10.5281/zenodo.20683746
- When Biology Crosses Categories Before Medicine Does — Founder Report, June 2026. doi: 10.5281/zenodo.20684028
- The Translational Gap in Metabolic Disease — Insight, June 2026. doi: 10.5281/zenodo.20684096
Scientific and strategic advisory only. Legal, regulatory, investment, clinical, and medical advice are outside standard engagements unless separately scoped in writing with the appropriate qualified contributor.